Tipsa om sidan
RSS
google +
Utskriftsvänlig version

Nyheter (En åldrande befolkning)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

Gardedam Therapeutics announces a crowdfunding campaign: Novel Parkinson's and Alzheimer's therapies    epda.eu.com

Gadedam Therapeutics (Gardedam) launched a crowdfunding campaign with the objective of raising $195,000 USD to support and advance its novel Parkinson's and Alzheimer's disease drug disovery efforts.[...]

Dietary fat intake and risk for Parkinson's disease    epda.eu.com

The study suggests that fat intake in general is not related to the risk for PD. The weak positive association between intake of n-6 PUFA and PD risk needs further investigation.[...]

Gait and balance in Parkinson's disease subtypes: objective measures and classification considerations    epda.eu.com

Clinical assessments of the disturbances seen in patients with the PIGD subtype are not consistent with objective measures; overlapping between the groups is seen in many objective features of gait a[...]

Mind matters: placebo enhances reward learning in Parkinson's disease    epda.eu.com

Authors found that the mere expectation of dopamine release enhanced reward learning and modulated learning-related signals in the striatum and the ventromedial prefrontal cortex. These effects were [...]

Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease    epda.eu.com

Study findings support the hypothesis that nigrostriatal dopaminergic deficit is associated with executive impairment, but not to memory or visuospatial impairment, in early PD.[...]

Norepinephrine Deficiency in Parkinson's Disease: The Case for Noradrenergic Enhancement    epda.eu.com

In addition to reducing the consequences of deficient noradrenergic signaling, enhancement strate gies have the potential for augmenting the effects of dopaminergic therapies in PD. Furthermore, earl[...]

CHMP Recommends Approval of Xadago™ (Safinamide) to Treat Parkinson´s Disease in the EU    epda.eu.com

First New Chemical Entity (NCE) in 10 years to receive a positive opinion from CHMP for the treatment of Parkinson's disease (PD) patients[...]

Drugs for Parkinson's disease can turn patients into gamblers, sex addicts and compulsive shoppers    epda.eu.com

Drugs commonly prescribed to treat Parkinson's disease increase the risk of behaviours such as sex addiction, compulsive shopping and gambling, research has found.[...]

Functional connectivity and cognitive decline over 3 years in Parkinson disease    epda.eu.com

In this fMRI study in PD, authors demonstrated a progressive loss of resting-state functional connectivity over a period of 3 years for multiple brain regions, especially in posterior parts of the br[...]

DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro    epda.eu.com

The significant effects of sex, diplotype, and brain region suggest that hypermethylation of the MAPT gene is neuroprotective by reducing MAPT expression. The effect of vitamin E on MAPT represents a[...]

Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson's disease    epda.eu.com

Demographic information, motor and non-motor symptom measurements were performed by face-to-face interview using specific scales. Scores and frequencies of symptoms were compared between male and fem[...]

Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease    epda.eu.com

Conclusions: This is the first report of a relationship between serum UA and presence/progression of multiple NMS in de novo PD, providing additional evidence of the reliability of UA as a biomarker [...]

Models of α-synuclein aggregation in Parkinson's disease    epda.eu.com

In this review authors focus on α-syn aggregation in the human disorder, its genetics and the availability of experimental models. Indeed, evidences show that dopamine (DA) metabolism may be related [...]

Helicobacter Pylori infection is associated with worse severity of parkinson's disease    epda.eu.com

This is the largest cross-sectional study to demonstrate an association between HP positivity and worse PD motor severity.[...]

22 year-old director sets out to propel Parkinson's into the limelight of film festivals around the world    epda.eu.com

After already being nominated for a Grierson award, one of the most prestigious documentary awards in the UK, Sam Oldmeadow is aiming to reach as many people as possible on the topic of Parkinson's u[...]

Frequency of Cholinergic & Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson's .....    epda.eu.com

Cortical cholinergic denervation is a major neurodegeneration associated with progressive declines across the spectrum of cognitive impairment in PD and typically occurs in the context of significant[...]

Press Centre - Major contract to support new pan-EU pension fund    europa.eu

The European Commission has made a key step on the way to establishing a new pan-European pension arrangement, designed to boost research mobility in Europe. It announced today (16 December 2014) the[...]

Yumanity Therapeutics Launched to Identify and Develop New Therapies for Neurodegenerative Diseases    epda.eu.com

Company formed to Discover Disease Modifying Therapies for Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis[...]

Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites    epda.eu.com

Provider costs were similar for the 144 GPi and 130 STN patients (GPi: $138,044 vs. STN: $131,822; difference = $6,222, 95% confidence interval [CI]: $42,125 to $45,343). Societal costs were also sim[...]

EPDA Move for Change survey shows Parkinson's care standards are lagging just one in 10 patients are diagnosed by a disease ex    epda.eu.com

Care provision in Parkinson's disease is falling dismally short of the standards patients and carers have every right to expect, research across Europe indicates.[...]

Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's: An international multicenter study    epda.eu.com

Results: The results demonstrate that EMO periods are common and occur in 59.7% of subjects across all disease stages in line with other reports. However, importantly, in 88.0% of those, EMOs were fo[...]

Back to the basics: regular exercise matters in Parkinson's: Results from the National Parkinson Foundation registry study    epda.eu.com

Regular exercisers at baseline was associated with better QOL, mobility, and physical function, less progression of disease, less caregiver burden and less cognitive decline one year later, after con[...]

Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series    epda.eu.com

Discussion: Hypersexuality and delusional jealousy may occur independently in PD patients on dopamine agonist therapy, but may develop together probably reflecting a common alteration of sexuality (s[...]

Does a specialist unit improve outcomes for hospitalized patients with Parkinson's disease?    epda.eu.com

The general ward care (n=20) and the Specialist Parkinson's Unit care (n=24) groups had similar baseline characteristics. On the specialist unit: less Parkinson's medication was omitted (13% v 20%, p[...]

Effects of cognitive training in Parkinson's Disease: a randomized controlled trial    epda.eu.com

Cognitive and affective functions can be improved by cognitive trainings in PD patients. Specific effects (e.g. on memory and working memory versus depression) seem to be dependent on the type of tra[...]

The Cognition & Emotional Well-being indices of the Parkinson's Disease Questionnaire-39: What do they really measure?    epda.eu.com

Conclusions: The PDQ-39 Cognition index may be more related to mood functioning, as opposed to cognitive functioning, and should not be considered a proxy for cognitive functioning. Future studies ar[...]

Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease    epda.eu.com

Conclusions: Hippocampal volume is a major factor predicting the development of mild cognitive impairment and dementia in PD. White matter hyperintensity also contributes to the longitudinal cognitiv[...]

Comparison of sleep and other non-motor symptoms between SWEDDs patients and de novo Parkinson´s disease patients    epda.eu.com

Conclusions: The patients with SWEDDs have less non-motor problems than newly diagnosed untreated PD patients. Given the difficulty distinguishing between SWEDDs and early PD, identifying some of non[...]

Effects of augmented visual feedback during balance training in Parkinson's disease: A pilot randomized clinical trial    epda.eu.com

VFT proved to be a feasible and safe approach to balance therapy for patients with PD. In this proof-of-concept study VFT was not superior over conventional balance training although observed trends [...]

Freezing of Gait subtypes have different cognitive correlates in Parkinson's disease    epda.eu.com

Conclusion: Aside from pharmacological differences, unresponsive FOG is associated with executive and visuospatial dysfunction implicating frontostriatal pathways while responsive FOG is associated w[...]

Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's Disease    epda.eu.com

Conclusion: In Parkinson's disease, REM Sleep Behavior Disorder is not associated with impulse control disorder. The results of this study do not support the notion that PSG-confirmed RBD and ICD sha[...]

Neural correlates of progressive reduction of bradykinesia in de novo Parkinson's disease    epda.eu.com

Results suggest that the ACC and the cerebellum (inferior semilunar lobule) are associated with the severity of SE. Taken together with DTI findings, the present study proposes that ACC may have an i[...]

Risk of Parkinson's disease following severe constipation: A nationwide population-based cohort study    epda.eu.com

The association between constipation at the beginning of the study and the incidence of PD was examined using a Cox regression model. Information regarding comorbidities and concomitant medications u[...]

Lucilla Bossi from Parkinson Italia honoured with Medtronic's Bakken Award    epda.eu.com

The Bakken Award recognizes outstanding individuals who, with the help of medical technology, have overcome health challenges and are now making significant contributions in their communities.[...]

Ensuring good nutritional status in patients with Parkinson's disease: challenges and solutions    epda.eu.com

The means of ensuring good nutritional status in PD range from providing adequate energy and nutrients for the body, to considering in a broader perspective, the management of motor and nonmotor symp[...]

Parkinson's Disease Severity and Use of Dopaminergic Medications    epda.eu.com

The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for ag[...]

Interleaved programming of subthalamic deep brain stimulation to avoid adverse effects and preserve motor benefit in Parkinson's    epda.eu.com

Interleaved stimulation (ILS) is a newer programming technique that attempts to optimize the stimulation field, improving control of symptoms while minimizing stimulation-induced adverse effects. A r[...]

Levodopa: Effect on cell death and the natural history of Parkinson's disease    epda.eu.com

This review article considers the question of whether or not levodopa is toxic in Parkinson's disease (PD). l-dopa is the most effective symptomatic treatment for PD and has provided benefit for mill[...]

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial    epda.eu.com

Study findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives a[...]

Mendelian randomization of serum urate and Parkinson's disease progression    epda.eu.com

The study was conducted among participants in DATATOP and PRECEPT, two randomized trials among patients with early PD. The 808 patients with available DNA were genotyped for three SLC2A9 single nucle[...]

Study establishes connection between gut microbiota and Parkinson's disease    epda.eu.com

Parkinson's disease sufferers have a different microbiota in their intestines than their healthy counterparts, according to a study conducted at the University of Helsinki and the Helsinki University[...]

Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson's Disease    epda.eu.com

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson's disease (PD). OFF episo[...]

Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson's Disease    epda.eu.com

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson's disease (PD). OFF episo[...]

Distinguishing Idiopathic Parkinson's From Other Parkinsonian Syndromes By Breath Test    epda.eu.com

Conclusions: Exhaled breath analysis with nanoarray is a promising approach for a non-invasive, inexpensive, and portable technique for differentiation between different Parkinsonian states. A larger[...]

Anxiety in Parkinson's disease: symptom dimensions and overlap with depression and autonomic failure    epda.eu.com

Conclusion: Anxiety in PD comprises affective and somatic symptom dimensions. The affective subscale of the BAI is not influenced by motor or autonomic symptoms, and may therefore prove useful for fu[...]

Parkinson's Vaccine: EU-Team Launches Clinical Trial    epda.eu.com

A novel Parkinson's vaccine will now be tested in a clinical Phase I trial in Austria by an EU-funded consortium. The vaccine was developed by the Austrian biotech company AFFiRiS AG and targets a pr[...]

ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson's Dis    epda.eu.com

Data from an analysis of Phase III studies in patients with PDP showed that treatment with NUPLAZID reduced caregiver burden compared to PDP patients on placebo.[...]

Longitudinal midbrain changes in early parkinson's disease: Iron content estimated from R2*/MRI    epda.eu.com

Conclusions: High field MRI demonstrates lateral SNc abnormalities that progress over 3 years in early PD consistent with increased iron content in those with more advanced disease, corresponding to [...]

Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson's disease    epda.eu.com

Study data are in agreement with (a) the Continuous Dopaminergic Stimulation (CDS) theory which states that continuous stimulation of the basal ganglia enhances motor, psychiatric and cognitive funct[...]

Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease    epda.eu.com

The effect of nicotine and some of its derivatives on dopaminergic neurons viability, neuroinflammation, and motor and memory functions, have been investigated using cellular and rodent models of PD.[...]

Mitochondrial dysfunction in Parkinson's disease: a possible target for neuroprotection    epda.eu.com

This review will discuss the evidence supporting mitochondrial dysfunction in Parkinson's disease pathology as well as treatment strategies that target the mitochondria.[...]

Gut microbiota are related to Parkinson's disease and clinical phenotype    epda.eu.com

Study findings suggest that the intestinal microbiome is altered in PD and is related to motor phenotype. Further studies are warranted to elucidate the temporal and causal relationships between gut [...]

Taste function in early stage treated and untreated Parkinson's disease    epda.eu.com

Study findings suggest that suprathreshold measures of taste function are influenced by PD and that this disease differentially influences taste function on anterior (CN VII) and posterior (CN IX) to[...]

Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease    epda.eu.com

Here, authors provide an overview of these recent advances, with a particular emphasis on the neurobiological correlates reported in animal models and patients along with their genetic underpinnings.[...]

Stem cells from adult nose tissue used to cure Parkinson's disease in rats    epda.eu.com

Scientists have for the first time used adult human stem cells to cure rats with Parkinson's disease, a neurodegenerative illness that currently has no cure.[...]

Controversial fetal cell transplants revived for Parkinson's trials    epda.eu.com

For the last 25 years, using fetal tissue for scientific research has largely fallen out of favor in both the European and U.S. scientific communities. One of the most publicised uses of the controve[...]

Brains in the balance: New $11.5M grant fuels University of Michigan Parkinson's disease research center to aid patients    epda.eu.com

NIH grant creates Udall Center of Excellence for Parkinson's Disease Research focused on developing a treatment to prevent falls.[...]

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics    epda.eu.com

The pharmacokinetics of l-dopa tend to predict some of problems that can emerge during chronic therapy, which can be linked with its irregular uptake and marked dose-by-dose variability in plasma con[...]

Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson's Disease    epda.eu.com

Head-to-head trials are needed in order to fully define the role of pramipexole ER relative to other once-daily formulations of DAs (oral ropinirole and transdermal rotigotine). Nonetheless, by reduc[...]

Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations    epda.eu.com

This study reveals widespread hemodynamic alterations in PD. However, within a functionally abnormal occipital lobe, those with PDVH have even lower ALFF than non-hallucinators, but have higher occip[...]

Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch:    epda.eu.com

This study suggests that a switch from oral anti-PD medications to rotigotine transdermal patch may improve existing GI symptoms among patients with PD. Additional controlled studies are needed to co[...]

Teikoku Pharma USA Announces Positive Study Results of 7-Day Patch for Parkinson's Disease    epda.eu.com

Teikoku Pharma USA announced positive results of a recently completed bioavailability (BA) study examining the delivery of TPU-002RA, a 7-day rasagiline patch, for Parkinson's disease.[...]

Gardedam Therapeutics announces a crowdfunding campaign: Novel Parkinson's and Alzheimer's therapies    epda.eu.com

Gadedam Therapeutics (Gardedam) launched a crowdfunding campaign with the objective of raising $195,000 USD to support and advance its novel Parkinson's and Alzheimer's disease drug disovery efforts.[...]

Life expectancy in the EU still on the rise: launch of EU at Glance report    europa.eu

European Commission - Press Release details page - European Commission - Statement Brussels, 03 December 2014 Joint statement by Vytenis Andriukaitis, EU Commissioner for Health and Food Safety, and[...]

Prediagnostic presentations of Parkinson's disease in primary care: a case-control study    epda.eu.com

Interpretation: A range of prediagnostic features can be detected several years before diagnosis of Parkinson's disease in primary care. These data can be incorporated into ongoing efforts to identif[...]

Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study    epda.eu.com

Levodopa (l-dopa) therapy in Parkinson's disease (PD) increases serum homocysteine levels because of its metabolism via catechol O-methyltransferase, which may lead to endothelial dysfunction.[...]

Factor analysis of The Hamilton Depression Rating Scale in Parkinson's disease    epda.eu.com

Conclusion: This analysis demonstrates that the factorial validity of the HAMD in PD is unsatisfactory. This implies that the scale is not appropriate for studying specific symptom domains of depress[...]

GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study    epda.eu.com

Conclusions: The mutational GBA status, rather than older age and age at onset, presents an important predictor for disease progression in this specific subgroup of PD patients.[...]

Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease    epda.eu.com

These results suggest that in newly diagnosed drug-naïve PD patients DAT availability might be different between ART and TD in relation to different disease severity.[...]

The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burd    epda.eu.com

The American Parkinson Disease Association is pleased to award research funding supporting seven Research grants to junior investigators pursuing research in Parkinson's disease, three Post-Doctoral [...]

Coordinated reset neuromodulation for Parkinson's disease: Proof-of-concept study    epda.eu.com

Results: Coordinated reset neuromodulation of the subthalamic nucleus (STN) applied to six PD patients in an externalized setting during three stimulation days induced a significant and cumulative re[...]

The prevalence of Parkinson's disease: A systematic review and meta-analysis    epda.eu.com

Authors sought to synthesize studies on the prevalence of PD to obtain an overall view of how the prevalence of this disease varies by age, by sex, and by geographic location.[...]

Parkinson's UK and Global Kinetics Corporation collaborate to provide promising new mHealth technology throughout UK    epda.eu.com

An innovative medical device designed in Australia to improve management of Parkinson's is to be made available in services in the United Kingdom, as part of a 12-month pilot project.[...]

Juncker Commission Work Programme 2015 – What to Expect for Public Health?    epha.org

November 20014 - Despite the existence of various pro-public health guidelines, Mr. Juncker's Commission Programme give cause for concern. The European Commission President Mr. Juncker and First Vice[...]

Functional connectivity and cognitive decline over 3 years in Parkinson disease    epda.eu.com

In this fMRI study in PD, authors demonstrated a progressive loss of resting-state functional connectivity over a period of 3 years for multiple brain regions, especially in posterior parts of the br[...]

Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study    epda.eu.com

Levodopa (l-dopa) therapy in Parkinson's disease (PD) increases serum homocysteine levels because of its metabolism via catechol O-methyltransferase, which may lead to endothelial dysfunction.[...]

Visual hallucinations in Parkinson's disease: Theoretical models    epda.eu.com

This review considers the leading hypothetical frameworks for visual hallucinations in Parkinson's disease, summarizing the key aspects of each in an attempt to highlight the aspects of the condition[...]

Success Stories - The Euro-Asian collaboration unravelling the mysteries of ageing    europa.eu

Much as we try to evade it, age catches us all. But are there ways to reverse or slow down the ageing process at a cellular level? An international project examining the biological changes that occur[...]

CSF biomarkers and clinical progression of Parkinson disease    epda.eu.com

Authors found evidence of a link between higher levels of αSyn at baseline and worsening of motor symptoms and cognitive speed over 2 years in PD. Increased αSyn might be a marker of more intense syn[...]

The role of the LRRK2 gene in Parkinsonism    epda.eu.com

In this review, authors discuss the pathology and clinical features which show diversity and variability of LRRK2-associated PD. In addition, they do a thorough literature review and provide theoreti[...]

Dopamine transporter imaging as a diagnostic tool for Parkinsonism and related disorders in clinical practice    epda.eu.com

DAT imaging may also have some prognostic value for disease progression. However, it has limited value in differentiating among degenerative causes of parkinsonism. Clinical assessment remains the mo[...]

Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease    epda.eu.com

Conclusions: Beta-blockers are associated with a lower risk of constipation, while dopaminergic treatments appear to increase risk of constipation.[...]

Parkinson's nurses: a light in the darkness    epda.eu.com

This article article explores the work of Parkinson's nurses, their benefits and how Parkinson's UK supports them to care for those affected by the condition.[...]

Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease    epda.eu.com

Together, these findings indicate that expansions in C9orf72 do not have a major role in the pathogenesis of PD. Testing for C9orf72 repeat expansions should only be considered in patients with PD wh[...]

Supporting people with Parkinson's in later life    epda.eu.com

All older people with Parkinson's will benefit from access to a specialist, comprehensive old-age assessment and nursing care that understands how symptoms can affect health and wellbeing, and is res[...]

Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats    epda.eu.com

In conclusion, authors here provide the first experimental evidence that different α-synuclein forms can propagate from the gut to the brain, and that microtubule-associated transport is involved in [...]

Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale    epda.eu.com

The AES-S is a reliable and valid questionnaire for detecting apathy in PD. For screening purposes a 33/34 cut-off score is indicated, but a 38/39 cut-off score is necessary when a high specificity i[...]

Dopaminergic medication does not improve stepping responses following backward & forward balance perturbations in Parkinson's    epda.eu.com

In conclusion, dopaminergic medication does not improve underscaling of stepping responses in PD. Therefore, other interventions are needed to improve these important defense postural reactions.[...]

Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease    epda.eu.com

Conclusion: In AJ-PD, G2019S mutation status is associated with better attention (Stroop Word Reading), executive function (Stroop Interference) and language (Category Fluency) after adjustment for P[...]

Physical activity and risk of Parkinson's disease in the Swedish National March Cohort    epda.eu.com

Study results indicate that a medium level of physical activity lowers Parkinson's disease risk.[...]

Great Lakes Neurotech enters medical device app market with Kinesia One for monitoring Parkinson's disease    epda.eu.com

Great Lakes NeuroTechnologies announced today they have successfully transitioned their Kinesia technology for objective monitoring of Parkinson's disease to an app platform.[...]

Correlation between the biochemical pathways altered by mutated parkinson-related genes and chronic exposure to manganese    epda.eu.com

The studies presented in this review attempt to describe the operative properties of the genes involved in generation of early and late onset of Parkinson's disease or Parkinson-like disorders and ho[...]

Applause sign in advanced Parkinson's disease    epda.eu.com

Conclusions: The applause sign is present in late stage PD and correlates with a higher degree of cognitive impairment as established with accepted clinimetric tests. A higher degree of frontal lobe [...]

Botulinum toxin type a potentiates effect of neuromotor rehabilitation of Pisa syndrome in Parkinson: A placebo controlled study    epda.eu.com

Botulin toxin (BT) may reduce muscle hyperactivity, therefore improving CT effectiveness. Authors evaluated whether the injection of incabotulinum toxin type A (iBTA) into the hyperactive trunk muscl[...]

Diagnostic accuracy of Parkinson's disease and atypical parkinsonism in nursing homes    epda.eu.com

In a large population of Dutch nursing home residents, 20% of diagnoses within the parkinsonian spectrum were inaccurate. Almost 9% of residents had inadvertently received a diagnosis of parkinsonism[...]

Cortical volume and folding abnormalities in Parkinson's disease patients with pathological gambling    epda.eu.com

This study demonstrates that combined grey matter atrophy and reduced lGI in the OFC differentiates PD patients with PG from those without PG, suggesting that this cortical area may play a critical r[...]

Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic    epda.eu.com

Conclusions: Over the last two decades, age at onset of PD appeared to shift progressively towards more advanced age. However, sequential, high quality population-based incidence studies are required[...]

Glucocerebrosidase mutations in primary parkinsonism    epda.eu.com

Conclusion: GBA dysfunction is relevant for synucleinopathies, such as PD and DLB, except for MSA, in which pathology involves oligodendrocytes, and the tauopathies PSP and CBD. The risk of developin[...]

Lifetime exposure to Estrogens and Parkinson's disease in California teachers    epda.eu.com

Conclusions: These results provide some support for the hypothesis that lifelong high estrogen is protective in PD, suggesting that the level and persistence of exposure over the long term may be imp[...]

Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease    epda.eu.com

Conclusions: MoCA is a reliable tool in predicting cognitive decline in early PD. A MoCA score of 26 significantly increases the risk for progressive cognitive decline.[...]

Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS    epda.eu.com

Results: Of these three frequent, and often inter-twined, non-motor complications, greater daytime sleepiness and fatigue were associated with worse cognitive impairment across the full spectrum of P[...]

The Future of Research in Parkinson Disease    epda.eu.com

There are many unanswered questions about Parkinson disease (PD), but as a result of advances in genetics, proteomics, metabolomics, epigenetics, imaging, and other novel techniques, remarkable progr[...]

Which features of Parkinson's Disease Predict Earlier Exit from the Workforce?    epda.eu.com

Conclusion: Demographics, disease duration, and mental health contribute to LWF, but not motor severity. Age, gender and income contributions are difficult to modify but important to recognize. Worse[...]

Success Stories - Expanding insight into Alzheimer's disease    europa.eu

Chronic neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's, are all characterised by an inflammatory reaction within the brain. Until now, some of the factors behind this r[...]

Great Lakes Neurotech enters medical device app market with Kinesia One for monitoring Parkinson's disease    epda.eu.com

Great Lakes NeuroTechnologies announced today they have successfully transitioned their Kinesia technology for objective monitoring of Parkinson's disease to an app platform.[...]

Trinity scientists make breakthrough in understanding Parkinson's disease    epda.eu.com

Trinity scientists make breakthrough in understanding how parkin, a gene implicated in Parkinson's disease, controls the repair and replacement of nerve cells.[...]

Increased risk of Parkinson's disease in cataract patients: A population-based cohort study    epda.eu.com

Conclusions: Overall, this study discloses a 26% increased hazard of Parkinson's disease in cataract patients. Further studies are required to investigate whether cataracts are one of non-motor manif[...]

DNAJC13 genetic variants in parkinsonism    epda.eu.com

Conclusion: Although the contribution of rare genetic variation in DNAJC13 to parkinsonisms remains to be further elucidated, this study suggests that, in addition to p.N855S, other rare variants mig[...]

Wearing-off detection in clinical practice: The wearing off real practice Key (WORK-PD) study in Parkinson's disease    epda.eu.com

Study data from a large Italian cross-sectional sample of 532 consecutive PD patients recruited from 6 different neurological outpatient units, specializing in movement disorders, confirmed that WOQ-[...]

Neuroimaging in Parkinson disease: from research setting to clinical practice    epda.eu.com

This Review discusses the lessons learnt from decades of neuroimaging research in PD, and the promising new approaches with potential applicability to clinical practice.[...]

Clinical markers for identifying cholinergic deficits in Parkinson's disease    epda.eu.com

The combination of rapid eye movement (REM) sleep behavior disorder (RBD) symptoms and fall history showed highest diagnostic accuracy (81.1%) for predicting combined thalamic and cortical cholinergi[...]

Researchers debunk myth about Parkinson's disease    epda.eu.com

BRAIN RESEARCH - Using advanced computer models, neuroscience researchers at the University of Copenhagen have gained new knowledge about the complex processes that cause Parkinson's disease. The fin[...]

Survey reveals knowledge gaps among Parkinson's patients and caregivers    epda.eu.com

A recent survey of more than 1,500 Parkinson's disease (PD) patients, caregivers and physicians reveals that information and specialized care can help patients become more engaged in their own treatm[...]

Canadian Study of Neurological Conditions Provides New Vital Information on the Impact of Parkinson's Disease    epda.eu.com

Parkinson Society Canada is excited to share today's release of the report on The National Population Health Study of Neurological Conditions by the Public Health Agency of Canada in partnership with[...]

Neurotransmitter receptor density changes in Pitx3ak mice A model relevant to Parkinson's disease    epda.eu.com

Authors demonstrated striking differential changes of neurotransmitter receptor densities for numerous receptor types and brain regions, respectively. Most prominent, a strong up-regulation of GABA r[...]

Fall frequency, predicting falls & participating in falls Research: Similarities among people with Parkinson's with & without Co    epda.eu.com

Fall rates (falls/person during follow-up) were similar among people with and without CI. Falls and difficulty turning were more sensitive predictors of falling in those with CI than those without: a[...]

Theta burst stimulation over the supplementary motor area in Parkinson's disease    epda.eu.com

To investigate whether a period of continuous theta burst stimulation (cTBS) over the supplementary motor area (SMA) induces cortical plasticity and thus improves bradykinesia in Parkinson's disease [...]

Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database    epda.eu.com

Conclusions: The specific and sensitive definitions of disease bracket the true values; the relatively small range indicates that the current study provides good estimations of incidence and prevalen[...]

The National Parkinson Foundation Launches CareMAP: An Online Guide to Caring for Someone with Advanced Parkinson's Disease    epda.eu.com

The National Parkinson Foundation (NPF) announced the launch of a new online guide, CareMAP, which provides practical suggestions for coping with the complex problems that arise as a result of advanc[...]

Parkure: Finding a cure for Parkinson's disease    epda.eu.com

Parkure is looking to raise up to £150,000 from crowdfunding, in a campaign starting on the 5th of November, to address the unmet need for a cure for the disease, which affects an estimated 127,000 p[...]

Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review    epda.eu.com

Conclusion: Endurance exercise training improves physical conditioning in PD patients; however, to date, there is insufficient evidence to include endurance exercise training as a specific treatment [...]

Formulations of hormone therapy and risk of Parkinson's disease    epda.eu.com

The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These find[...]

Interventions for fatigue in Parkinson's disease: A systematic review and meta-analysis    epda.eu.com

Currently insufficient evidence exists to support the treatment of fatigue in PD with any drug or nondrug treatment. Further study is required.[...]

Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study    epda.eu.com

Conclusion: Subjects with DAT deficit who do not meet criteria for a diagnosis of PD can be identified by olfactory testing. Sequential biomarker assessment may identify those at risk of PD.[...]

Pooled analysis of phase III with entacapone in Parkinson's disease    epda.eu.com

Conclusions: Entacapone improved daily OFF- and ON-times by a mean of 0.8 h compared with placebo across the four pooled efficacy studies and was generally well tolerated. The results of this pooled [...]

Global Kinetics Corporation Announces FDA Clearance of the Personal KinetiGraph™ for Assessment of Parkinson's Disease Symptoms    epda.eu.com

Global Kinetics Corporation, a leading mobile health technologies company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the marketing of the company's Personal KinetiG[...]

Cortical thinning associated with mild cognitive impairment in Parkinson's disease    epda.eu.com

Patients with MCI showed regional cortical thinning in parietotemporal regions, increased global atrophy (global cortical thinning, total gray matter volume reduction, and ventricular enlargement), a[...]

Pallidal gap junctions-triggers of synchrony in Parkinson's disease?    epda.eu.com

In this study, confocal imaging was used to detect connexin-36, the major neural gap junction protein, in postmortem tissues of PD patients and control subjects in the putamen, subthalamic nucleus (S[...]

EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease    epda.eu.com

Based on this open-label, nonrandomized, comparative study, authors report that, in advanced Parkinson's patients, both IJLI and Apo infusion therapy appear to provide a robust improvement in motor s[...]

The impact of subthalamic deep brain stimulation on caregivers of Parkinson's disease patients: an exploratory study    epda.eu.com

Study results show that at 1-year FU over 50 % of the caregivers rated their subjective well-being as negative. Especially older and more depressed caregivers are at risk. These caregivers and their [...]

Scientists create Parkinson's disease in a dish    epda.eu.com

A team of scientists led by The New York Stem Cell Foundation (NYSCF) Research Institute successfully created a human stem cell disease model of Parkinson's disease in a dish.[...]

'Pocket doctor' phone app could measure Parkinson's progression    epda.eu.com

Parkinson's disease and other degenerative motor system disorders are notoriously difficult to diagnose accurately. But now, new research has resulted in a new application that enables smartphones to[...]

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson's Disease, and Diabetic Neuropathy    epda.eu.com

KineMed, Inc. today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: Compositions and Methods of Treatment Using Mod[...]

Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model    epda.eu.com

Authors found that low-dose lithium treatment prevented motor impairment as demonstrated by the open field test, pole test, and rearing behavior. Furthermore, lithium prevented dopaminergic striatal [...]

Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale    epda.eu.com

Scores of more detailed assessments, as the MDS-UPDRS, have not been translated to a grading that allows assignment of score sections to severity levels. The objective of the present study is to dete[...]

Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment & Dementia Rating Scale-2 scores in Parkinson's    epda.eu.com

The primary aim of this study was to apply a simple and reliable algorithm for the conversion of MoCA to MMSE scores in PD patients. A secondary aim was to apply this algorithm for the conversion of [...]

Complementary & Alternative Management of Parkinson's Disease: An Evidence-Based Review of Eastern Influenced Practices    epda.eu.com

Study data link the increased kinase of the G2019S-LRRK2 mutation to neuronal dysfunction and demonstrate the power of the Drosophila visual system in assaying the neurological effects of genetic dis[...]

Parkinson's Disease Foundation Highlights Diverse Contributions of Care Partners    epda.eu.com

As part of National Family Caregivers Month this November, the Parkinson's Disease Foundation (PDF) recognizes the diverse contributions of loved ones of people with Parkinson's disease, with its All[...]

Apathy in untreated early-stage Parkinson disease: Relationship with other non-motor symptoms    epda.eu.com

Apathetic patients had significantly more severe motor symptoms (P < 0.001) and a lower cognitive status (P = 0.032) than non-apathetic patients. When considering non-motor symptoms, apathy was si[...]

Head injury, α-synuclein genetic variability and Parkinson's disease    epda.eu.com

The study finds some evidence that head injury and D4S3481 or rs356165 variants jointly increase the risk of PD but little evidence of interaction.[...]

ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson's Disease Psycho    epda.eu.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central ne[...]

Action tremor in Parkinson's disease: frequency and relationship to motor and non-motor signs    epda.eu.com

Conclusions Action tremor is a relatively frequent motor sign in patients with Parkinson's disease staging 12 on the HoehnYahr scale. Action tremor correlates with rest tremor and rigidity and may be[...]

Alpha-synuclein and tau: teammates in neurodegeneration?    epda.eu.com

Moreover, tau and alpha-synuclein appear to promote the fibrillization and solubility of each other in vitro and in vivo. This suggests that interactions between tau and alpha-synuclein form a delete[...]

Unprecedented multi-stakeholder Parkinson's disease initiative 'My PD Journey' aims to improve the lives of thousands people    epda.eu.com

The European Parkinson's Disease Association (EPDA) has launched a first-of-its-kind initiative for people with Parkinson's in Europe entitled My PD Journey.[...]

The multi-stakeholder Parkinson's disease initiative 'My PD Journey' begins its first major research project to identify whe    epda.eu.com

The European Parkinson's Disease Association (EPDA) has launched a major research project across Europe to identify good practice and to seek out the major gaps in Parkinson's disease care that curre[...]

The multi-stakeholder Parkinson's disease initiative 'My PD Journey' begins its first major research project to identify whe    epda.eu.com

The European Parkinson's Disease Association (EPDA) has launched a major research project across Europe to identify good practice and to seek out the major gaps in Parkinson's disease care that curre[...]

Unprecedented multi-stakeholder Parkinson's disease initiative 'My PD Journey' aims to improve the lives of thousands people    epda.eu.com

The European Parkinson's Disease Association (EPDA) has launched a first-of-its-kind initiative for people with Parkinson's in Europe entitled My PD Journey.[...]

Effects of Tyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial    epda.eu.com

Study results were inconclusive as to whether an increase in plasma tyrosine has an effect on OH in subjects with PD. An increase in plasma tyrosine had no effect on BP or autonomic responses in subj[...]

Midlife migraine and late-life parkinsonism    epda.eu.com

These findings suggest there may be a common vulnerability to, or consequences of, migraine and multiple indicators of parkinsonism. Additional genetic and longitudinal observational studies are need[...]

A novel treatment target for Parkinson's disease    epda.eu.com

For the first time here authors propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover they predict that the neuroprotective roles of either niacin or butyrates in [...]

Akinetic-Rigid and Tremor-Dominant Parkinson's Disease Patients Show Different Patterns of Intrinsic Brain Activity    epda.eu.com

Overall, study findings highlight the involvement of default mode network (DMN) and STC circuit both in AR and TD subtypes, but also underscore the importance of integrating mesolimbic-striatal and C[...]

Program for Action on Global Health, Brussels, 28 October 2014 - Draft agenda available    europa.eu

European Commission - Brussels, 28 October 2014 [...]

Changes in 'Parkinson's walk' predict dementia    epda.eu.com

Political affairs and policy Medical and pharmaceutical Resources and publications Changes in 'Parkinson's walk' predict dementia "Subtle changes in the walking pattern of Parkinson's patients could[...]

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease    epda.eu.com

Twenty-six loci were identified as having genome-wide significant association; these and 6 additional previously reported loci were then tested in an independent set of 5,353 cases and 5,551 controls[...]

Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson's disease    epda.eu.com

Study data are in agreement with (a) the Continuous Dopaminergic Stimulation (CDS) theory which states that continuous stimulation of the basal ganglia enhances motor, psychiatric and cognitive funct[...]

The evolution of mild parkinsonian signs in aging    epda.eu.com

The study reveals that gait velocity was the main predictor of persistent mild parkinsonian signs, whereas cardiovascular disease was associated with new-onset mild parkinsonian signs. These findings[...]

miRNA expression is highly sensitive to a drug therapy in Parkinson's disease    epda.eu.com

Conclusions: It is probable that miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes[...]

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease    epda.eu.com

This is the first study indicating that the SLC6A3/DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease. This effect is stronger for conditions [...]

Changes in Vowel Articulation with Subthalamic Nucleus Deep Brain Stimulation in Dysarthric Speakers with Parkinson's Disease    epda.eu.com

Results suggest that STN DBS may improve articulation in dysarthric speakers with PD, in terms of range of movement. Optimization of the electrical parameters for each patient is important and may le[...]

Autonomic symptoms in Parkinson's disease    epda.eu.com

Despite a growing interest in the problem of autonomic dysfunction in PD, few studies have focused on autonomic dysfunction in PD, the patient's perspective about autonomic symptoms, and the relative[...]

Neural Substrates of Cognitive Subtypes in Parkinson's Disease: A 3-Year Longitudinal Study    epda.eu.com

Conclusions: These results suggest that visuoperceptual impairment and the early involvement of the posterior neocortex may be risk factors for rapid symptomatic progression and dementia in PD[...]

The major impact of freezing of gait on quality of life in Parkinson's disease    epda.eu.com

While sleepwake disturbance and mood have a significant negative impact on HRQoL in PD, the emergence of FOG represents the most substantial predictor among patients in the earlier clinical stages of[...]

Alternations of Mean Diffusivity of Pedunculopontine Nucleus Pathway in Parkinson's Disease Patients with Freezing of Gait    epda.eu.com

Conclusions: Based on study results, microstructural changes of pedunculopontine nucleus and connected subcortical structures are closely related with FOG in PD patients.[...]

Drugs for Parkinson's disease can turn patients into gamblers, sex addicts and compulsive shoppers    epda.eu.com

Drugs commonly prescribed to treat Parkinson's disease increase the risk of behaviours such as sex addiction, compulsive shopping and gambling, research has found.[...]

Upregulation of GPR109A in Parkinson's Disease    epda.eu.com

The findings of associations among the GPR109A receptor, niacin levels and night-sleep function in individuals with PD are novel. Further studies are needed to understand the pathophysiological mecha[...]

Predictors of the psychosocial impact of being a carer of people living with Parkinson's disease: A systematic review    epda.eu.com

Confident conclusions could not be drawn regarding the most important predictors that should be targeted in psychosocial interventions due to methodological weaknesses and lack of theoretical testing[...]

Active & healthy ageing - Just Published - EU Bookshop    europa.eu

A European innovation partnership[...]

The EPDA's My PD Journey Project starts work on a new Parkinson's disease Composite Quality of Life Scale    epda.eu.com

Work has begun to develop a new composite scale for motor and non-motor symptoms of Parkinson's disease.[...]

The EPDA's My PD Journey Project starts work on a new Parkinson's disease Composite Quality of Life Scale    epda.eu.com

Work has begun to develop a new composite scale for motor and non-motor symptoms of Parkinson's disease.[...]

Random Whole Body Vibration over 5 Weeks Leads to Effects Similar to Placebo: A Controlled Study in Parkinson's Disease    epda.eu.com

Conclusions. Random WBV training over 5 weeks seems to be less effective than reported in previous studies performing short-term training. The slight improvements in the FRT and TUG are not clinicall[...]

Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease    epda.eu.com

Although there was no significant difference between PD patients and control individuals regarding chemokines levels, our preliminary results showed that CXCL10/IP-10 may be associated with cognitive[...]

Mind matters: placebo enhances reward learning in Parkinson's disease    epda.eu.com

Authors found that the mere expectation of dopamine release enhanced reward learning and modulated learning-related signals in the striatum and the ventromedial prefrontal cortex. These effects were [...]

Autonomic Dysfunction in Parkinson's Disease With and Without Deep Brain Stimulation    epda.eu.com

New findings from The Parkinson Alliance (PA) survey entitled Autonomic Dysfunction in Parkinson's Disease With and Without Deep Brain Stimulation show that autonomic dysfunction was highly prevalent[...]

Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study    epda.eu.com

This study demonstrates that neurocognitive deficits are common even in recently diagnosed patients with Parkinson's disease, and that the associated regional brain activations are influenced by geno[...]

Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial    epda.eu.com

There was a significantly greater reduction in the off-time (p = 0.014) in the rotigotine group. Rotigotine was well tolerated, with serious adverse events being reported in only three patients in ea[...]

Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease    epda.eu.com

Together, these findings indicate that expansions in C9orf72 do not have a major role in the pathogenesis of PD. Testing for C9orf72 repeat expansions should only be considered in patients with PD wh[...]

New treatments for the motor symptoms of Parkinson's disease    epda.eu.com

Authors provide an update since 2011 on new formulations of current drugs, new drugs with promising results in Phase II and Phase III clinical trials, old drugs with new possibilities and some new po[...]

Predictors of dementia in Parkinson disease    epda.eu.com

Conclusion: Cardiovascular autonomic dysfunction, REM sleep behavior disorder, color discrimination ability, and gait dysfunction strongly predict development of dementia in Parkinson disease.[...]

A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine    epda.eu.com

Study results document for the first time a disturbance of ERK1/2 signaling regulation associated with apomorphine-induced involuntary movements in a genetic mouse model of synucleinopathy. This mous[...]

Parkinson disease and smoking revisited    epda.eu.com

Authors propose that ease of smoking cessation is an aspect of premanifest PD similar to olfactory dysfunction, REM sleep disorders, or constipation and suggests that the apparent neuroprotective eff[...]

Dopaminergic agents and nutritional status in Parkinson's disease    epda.eu.com

Results: In linear regression, total levodopa (l-dopa) equivalent daily dose (LEDD) was associated with worse MNA (B = 0.14, 95% CI = 0.26-0.02; P = 0.019). This association remained significant only[...]

Parkinson's UK appoints Research Director to ignite industry collaboration    epda.eu.com

Parkinson's UK has appointed leading pharma industry expert Dr Arthur Roach as their Research Director in a bid to spearhead collaboration between Parkinson's medical research and industry.[...]

Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease    epda.eu.com

Study results suggest MMSE and the pentagon item reflect brain changes which at a regional level involve mainly posterior regions. Correlates of the pentagon item were seen in the same regions where [...]

Peripheral nervous system involvement in Parkinson's disease: evidence and controversies    epda.eu.com

In this review, authors discuss the different hypotheses, as well as our perspective on open issues and controversies.[...]

Abnormal MoCA and Normal Range MMSE scores in Parkinson disease without dementia: Cognitive and Neurochemical Correlates    epda.eu.com

Conclusion: PD subjects with normal range MMSE but abnormal MoCA scores had evidence of caudate nucleus dopaminergic denervation and mild cognitive changes, predominantly in executive function. The M[...]

Catechol-O-methyltransferase Val158Met polymorphism: Modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's    epda.eu.com

The purpose of this study was to characterize the correlation between the Val158Met polymorphism in the COMT gene and the motor complication wearing-off in Chinese PD patients. Authors have sequenced[...]

Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2    epda.eu.com

In conclusion, significant differences were not detected between R1441G-PD and i-PD in cognitive, depression and anxiety scales, or PD-MCI and PD-Dementia prevalence, and the cognitive profile was id[...]

Does a volume reduction of the parietal lobe contribute to freezing of gait in Parkinson's disease?    epda.eu.com

Study results suggest that a specific pattern of cortical volume reduction involving posterior parietal cortex contributes to the occurrence of FOG in PD. These data agree with the growing body of ev[...]

Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life    epda.eu.com

Conclusions: PD-MCI is a significant, independent factor contributing to poorer QoL in patients with newly diagnosed PD. Those classified with greatest impairment (2.0 SD below normal values) have lo[...]

REM sleep behavior disorder: Association with motor complications and impulse control disorders in Parkinson's disease    epda.eu.com

Conclusion: Motor complications and ICRB are more frequent in patients with RBD than in patients without RBD. In addition, motor complications are related to RBD even after adjusting for age and dise[...]

Health-EU Newsletter - Active and Healthy Ageing    europa.eu

The European Innovation Partnership on Active and Healthy Ageing (EIP-AHA) has redefined the way we look at getting old. We are now more aware that the lifestyle choices we make today will greatly i[...]

Sensitive measures of executive dysfunction in non-demented Parkinson's diseas    epda.eu.com

No significant differences between groups were observed on widely used clinical measures. The PD patients scored lower than controls on the EXAMINER Executive Composite, Cognitive Control, and Workin[...]

Safinamide for the treatment of Parkinson's disease    epda.eu.com

In this work authors examine the biochemical properties of synthetic and natural molecules that are capable of interfering on both DA system (via monoamine oxidase inhibition) and AS fibrillation.[...]

The Michael J. Fox Foundation and Intel join forces to improve Parkinson's disease monitoring and treatment through advanced tec    epda.eu.com

The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Intel Corporation announced today a collaboration aimed at improving research and treatment for Parkinson's disease - a neurodegenera[...]

Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats    epda.eu.com

In conclusion, authors here provide the first experimental evidence that different α-synuclein forms can propagate from the gut to the brain, and that microtubule-associated transport is involved in [...]

Dyskinesias and motor symptoms onset in Parkinson disease    epda.eu.com

Conclusions: The partial association between the body site of motor symptoms and of LID onset likely reflects pathophysiological mechanisms underlying LID.[...]

Rotigotine vs ropinirole in advanced stage Parkinson's disease: A double-blind study    epda.eu.com

Conclusions: Rotigotine was well tolerated at doses up to 16 mg/24 h and showed similar efficacy to ropinirole except that the application site reaction was much higher in the rotigotine group.[...]

MRI brain scans detect people with early Parkinson's    epda.eu.com

Oxford University researchers have developed a simple and quick MRI technique that offers promise for early diagnosis of Parkinson's disease[...]

Lundbeck receives grant from The Michael J. Fox Foundation for biological markers identification in Parkinson's disease    epda.eu.com

A Lundbeck research program aiming to increase the knowledge of how a specific change in a gene (Lrrk2) contributes to an increased risk of developing Parkinson's disease was granted DKK 3,5m from Th[...]

International Parkinson's Empowerment Summit 2014    epda.eu.com

The Davis Phinney Foundation and Move4Parkinson's invite people living with Parkinson's, their families and care partners to join them for a unique, international event in Dublin, Ireland.[...]

NIH scientists find six new genetic risk factors for Parkinson's    epda.eu.com

Using data from over 18,000 patients, scientists have identified more than two dozen genetic risk factors involved in Parkinson's disease, including six that had not been previously reported. The stu[...]

First clinical data of therapeutic Parkinson's disease vaccine encourages continued development    epda.eu.com

AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson´s disease. PD01A is the first therapy against the protei[...]

Distinguishing between Progressive Supranuclear palsy and Parkinson's disease    epda.eu.com

Progressive Supranuclear palsy (PSP) and Parkinson's Disease (PD) have overlapping symptoms but remain difficult to distinguish.[...]

Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study    epda.eu.com

Conclusion: Subjects with DAT deficit who do not meet criteria for a diagnosis of PD can be identified by olfactory testing. Sequential biomarker assessment may identify those at risk of PD.[...]

Frontal deficits differentiate progressive supranuclear palsy from Parkinson's disease    epda.eu.com

These findings suggest that more severe and prominent 'frontal' cognitive deficits in patients with progressive parkinsonism would be helpful in predicting progressive supranuclear palsy rather than [...]

7 tesla magnetic resonance imaging: A closer look at substantia nigra anatomy in Parkinson's disease    epda.eu.com

This review is designed to provide a better understanding of the correspondence between the outlines and subdivisions of the SN detected using different MRI contrasts and the histological organizatio[...]

Norepinephrine Deficiency in Parkinson's Disease: The Case for Noradrenergic Enhancement    epda.eu.com

In addition to reducing the consequences of deficient noradrenergic signaling, enhancement strate gies have the potential for augmenting the effects of dopaminergic therapies in PD. Furthermore, earl[...]

Parkinson's Disease, the Subthalamic Nucleus, Inhibition, and Impulsivity    epda.eu.com

Though the results are not always consistent, nevertheless, this body of evidence supports the role of the STN in inhibitory and executive control.[...]

Controversial fetal cell transplants revived for Parkinson's trials    epda.eu.com

For the last 25 years, using fetal tissue for scientific research has largely fallen out of favor in both the European and U.S. scientific communities. One of the most publicised uses of the controve[...]

Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors    epda.eu.com

Conclusions: Gender, age, disease duration and dementia all seem to contribute to the occurrence of swallowing disturbances independently. However, the role played by these factors in sub-groups of p[...]

Brains in the balance: New $11.5M grant fuels University of Michigan Parkinson's disease research center to aid patients    epda.eu.com

NIH grant creates Udall Center of Excellence for Parkinson's Disease Research focused on developing a treatment to prevent falls.[...]

Herbs treating Parkinson's disease    epda.eu.com

This article reviews herbs that have been documented to have a neuroprotective effect in vitro and in vivo Parkinson's disease (PD) model systems. Authors summarized the anti-Parkinsonian activities [...]

The dopaminergic system in upper limb motor blocks (ULMB) investigated during bimanual coordination in Parkinson's disease (PD)    epda.eu.com

The current study investigated the occurrence of ULMB in PD participants without ('off') and with ('on') dopamine replacement using bimanual wrist flexionextension with external auditory cues.[...]

Physical training prevents depressive symptoms and a decrease in brain-derived neurotrophic factor in Parkinson's disease    epda.eu.com

Study results demonstrate that exercise training was effective for neuroprotection in the striatum and the hippocampus in an experimental model of PD.[...]

Parkinson's disease and age: The obvious but largely unexplored link    epda.eu.com

The risk of Parkinson's disease increases dramatically in individuals over the age of 60 and it is estimated that more than 1% of all seniors have some form of the condition. In this review, authors [...]

Distinct phenotypes of speech and voice disorders in Parkinson's disease after subthalamic nucleus deep brain stimulation    epda.eu.com

Conclusions: Stuttering and breathy voice can be aggravated by STN-DBS, but are mainly due to aging or PD itself. Strained voice and spastic dysarthria are considered corticobulbar side effects.[...]

Parkinson's disease beyond 20 years    epda.eu.com

Objective: To characterise PD 20 years after onset, investigating the impact of age at onset and disease duration on the clinical picture and the predictors of outcomes in patients reaching the 20-ye[...]

Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease    epda.eu.com

Study findings support the hypothesis that nigrostriatal dopaminergic deficit is associated with executive impairment, but not to memory or visuospatial impairment, in early PD.[...]

The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burd    epda.eu.com

The American Parkinson Disease Association is pleased to award research funding supporting seven Research grants to junior investigators pursuing research in Parkinson's disease, three Post-Doctoral [...]

Comparison of sleep and other non-motor symptoms between SWEDDs patients and de novo Parkinson´s disease patients    epda.eu.com

Conclusions: The patients with SWEDDs have less non-motor problems than newly diagnosed untreated PD patients. Given the difficulty distinguishing between SWEDDs and early PD, identifying some of non[...]

Alpha-synuclein repeat variants and survival in Parkinson's disease    epda.eu.com

In this large consortium study, α-synuclein REP1 genotypes were not associated with survival in PD. Further studies of α-synuclein's role in disease progression and long-term outcomes are needed.[...]

Peptidoglycan recognition protein genes and risk of Parkinson's disease    epda.eu.com

Authors tested the hypothesis that variants in genes that encode PGRPs are associated with PD risk. Participants in two independent case-control studies were genotyped for 30 single-nucleotide polymo[...]

Magnetic resonance support vector machine discriminates essential tremor with rest tremor from tremor-dominant Parkinson disease    epda.eu.com

Results: SVM classification of individual patients showed that no single predictor was able to fully discriminate patients with tPD from those with rET. By contrast, when all predictors were combined[...]

Development and validation of a new screening questionnaire for dysphagia in early stages of Parkinson's disease    epda.eu.com

The two-phased project comprised the questionnaire, diagnostic scales construction (N=105), and a validation study (N=82). Data for the project were gathered from PD patients at a German Movement Dis[...]

Suprathreshold odor intensity perception in early-stage Parkinson's disease    epda.eu.com

Conclusions: Parkinson's disease (PD) influences suprathreshold estimates of perceived odor intensity, negating the notion that such perception might be spared in this disease. No association with do[...]

Reduced thalamic volume in Parkinson Disease with REM Sleep Behavior Disorder: volumetric study    epda.eu.com

Study findings suggest that the presence of RBD symptoms in PD patients is associated with a reduced thalamic volume suggesting a pathophysiologic role of the thalamus in the complex circuit causing [...]

Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease    epda.eu.com

In conclusion, study findings cast doubt on the pathogenic role of α-synuclein aggregates in elderly, but do suggest that the severity of neurodegeneration and local burden of α-synuclein pathologica[...]

High-frequency oscillations in Parkinson's disease: Spatial distribution and clinical relevance    epda.eu.com

Authors found a focal spatial distribution of high-frequency oscillations with highest power 2 mm below the dorsolateral border of the subthalamic nucleus. Within the subthalamic nucleus, power peake[...]

Association of COMT and MAO-B Gene Polymorphisms with motor complications in Parkinson's Disease in a Chinese population    epda.eu.com

Study findings suggest that polymorphisms in COMT and MAO-B may increase the risk of wearing-off and dyskinesias. COMT (GG) genotype may be the risk factor of wearing-off. While MAO-B (AG) genotype m[...]

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease    epda.eu.com

This 2-year, controlled study of add-on safinamide in mid-to-late Parkinson's disease with motor fluctuations, although not demonstrating an overall difference in dyskinesias between patients and con[...]

Natural history of falls in a population-based cohort of patients with Parkinson's disease: an 8-year prospective study    epda.eu.com

Nearly of the PD cohort reported falling after 8 years of follow-up. Disease-specific gait and axial impairments were the major risk factors for future falls in non-fallers at baseline. This has impl[...]

Relation Between Freezing of Gait and Frontal Function in Parkinson's Disease    epda.eu.com

This is the first study to assess the relation between FOG in the 'on' state and frontal dysfunction evaluated using Behavioral Assessment of the Dysexecutive Syndrome (BADS),[...]

New pan-European pension fund to boost researcher mobility    europa.eu

European Commission Press release Brussels, 1 October 2014 Mobility of researchers in Europe received a boost today with the launch of a consortium that aims to establish a new pan-European pension a[...]

Chromosome 22q11.2 deletion may contain a locus for recessive early-onset Parkinson's disease    epda.eu.com

Herein, authors propose a hypothesis that it is not the microdeletion per se that is responsible for the phenotype but rather a complete loss of function of a gene within the region due to the combin[...]

Cognitive and cortical thinning patterns of subjective cognitive decline in patients with and without Parkinson's disease    epda.eu.com

Study data show that cortical thinning and cognitive performance in patients with SCD may differ based on the presence of PD, suggesting that SCD in patients with PD reflects disease-related cortical[...]

Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG    epda.eu.com

These findings largely corresponded with the variables that were associated with the presence of dementia at baseline. In a stepwise regression model, higher age at baseline, fewer years of education[...]

The Impact of STN Deep Brain Stimulation on Speech in Individuals with Parkinson's Disease: The Patient's Perspective    epda.eu.com

Conclusion: DBS therapy's contribution to speech disturbance is gaining more attention, and the speech symptoms ensuing from and/or being exacerbated by DBS are in the incipient stages of being inves[...]

Confirmation of the association between LRRK2 R1628P variant and susceptibility to Parkinson's disease in the Thai population    epda.eu.com

Authors confirm the association between p.R1628P and risk of developing PD in the appropriated sample-sized cohort. Certain LRRK2 variants appear to be generally distributed among East Asians, howeve[...]

Freezing of Gait subtypes have different cognitive correlates in Parkinson's disease    epda.eu.com

Conclusion: Aside from pharmacological differences, unresponsive FOG is associated with executive and visuospatial dysfunction implicating frontostriatal pathways while responsive FOG is associated w[...]

Motor impairment, depression, dementia: Which forms the impression of disease severity in Parkinson's disease?    epda.eu.com

Conclusion: The additional burden of dementia and depression was underestimated in the CGIS rating, suggesting that they are possibly relativized against the motor impairment.[...]

Neural correlates of progressive reduction of bradykinesia in de novo Parkinson's disease    epda.eu.com

Results suggest that the ACC and the cerebellum (inferior semilunar lobule) are associated with the severity of SE. Taken together with DTI findings, the present study proposes that ACC may have an i[...]

Parkinson's UK and Global Kinetics Corporation collaborate to provide promising new mHealth technology throughout UK    epda.eu.com

An innovative medical device designed in Australia to improve management of Parkinson's is to be made available in services in the United Kingdom, as part of a 12-month pilot project.[...]

Risk of Parkinson's disease following severe constipation: A nationwide population-based cohort study    epda.eu.com

The association between constipation at the beginning of the study and the incidence of PD was examined using a Cox regression model. Information regarding comorbidities and concomitant medications u[...]

Course of psychiatric symptoms and global cognition in early Parkinson disease    epda.eu.com

Conclusion: Multiple NPS are more common in de novo, untreated patients with PD compared with the general population, but they also remain relatively stable in early disease, while global cognition s[...]

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial    epda.eu.com

Study findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives a[...]

Effects of augmented visual feedback during balance training in Parkinson's disease: A pilot randomized clinical trial    epda.eu.com

VFT proved to be a feasible and safe approach to balance therapy for patients with PD. In this proof-of-concept study VFT was not superior over conventional balance training although observed trends [...]

Formulations of hormone therapy and risk of Parkinson's disease    epda.eu.com

The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These find[...]

Gait and balance in Parkinson's disease subtypes: objective measures and classification considerations    epda.eu.com

Clinical assessments of the disturbances seen in patients with the PIGD subtype are not consistent with objective measures; overlapping between the groups is seen in many objective features of gait a[...]

Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's Disease    epda.eu.com

Conclusion: In Parkinson's disease, REM Sleep Behavior Disorder is not associated with impulse control disorder. The results of this study do not support the notion that PSG-confirmed RBD and ICD sha[...]

Mendelian randomization of serum urate and Parkinson's disease progression    epda.eu.com

The study was conducted among participants in DATATOP and PRECEPT, two randomized trials among patients with early PD. The 808 patients with available DNA were genotyped for three SLC2A9 single nucle[...]

Over 700 people take a step forward for Parkinson's at the European Unity Walk    epda.eu.com

The 2nd European Unity Walk took part in the beautiful heart of Luxembourg was a huge success marked by unity and public awareness.[...]

Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation    epda.eu.com

In this retrospective study, authors compared motor disease progression in Ashkenazi-Jewish (AJ) Parkinson's disease (PD) patients carrying the LRRK2*G2019S mutation with that of noncarriers.[...]

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease    epda.eu.com

Results demonstrated a significantly greater improvement in total UPDRS scores from baseline to week 18 in the rasagiline group compared with the placebo group (least squares [LS] mean difference  SE[...]

Cardiac stress test is normal in pre-motor Parkinson's disease    epda.eu.com

Authors retrospectively reviewed treadmill ergometric tests of a large cohort (n = 16,841) between 2000 and 2012, that attended the Executive Screening Survey (ESS) at Sheba Medical Center. Heart rat[...]

Cerebral microbleeds in patients with Parkinson's disease    epda.eu.com

The present data demonstrate that even though CMBs were inseparably associated with the presence of WMHs, CMBs occur more commonly in PD patients with dementia than in those without dementia. Additio[...]

Subjective memory complaints, depressive symptoms and cognition in Parkinson's disease patients    epda.eu.com

Background and purpose: The goal of this study was to establish the prevalence of subjective memory complaints (SMCs) and depressive symptoms (DS)s and their relation to cognitive functioning in pati[...]

Dopaminergic medication does not improve stepping responses following backward & forward balance perturbations in Parkinson's    epda.eu.com

In conclusion, dopaminergic medication does not improve underscaling of stepping responses in PD. Therefore, other interventions are needed to improve these important defense postural reactions.[...]

Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale    epda.eu.com

The AES-S is a reliable and valid questionnaire for detecting apathy in PD. For screening purposes a 33/34 cut-off score is indicated, but a 38/39 cut-off score is necessary when a high specificity i[...]

Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's: An international multicenter study    epda.eu.com

Results: The results demonstrate that EMO periods are common and occur in 59.7% of subjects across all disease stages in line with other reports. However, importantly, in 88.0% of those, EMOs were fo[...]

Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites    epda.eu.com

Provider costs were similar for the 144 GPi and 130 STN patients (GPi: $138,044 vs. STN: $131,822; difference = $6,222, 95% confidence interval [CI]: $42,125 to $45,343). Societal costs were also sim[...]

Does a specialist unit improve outcomes for hospitalized patients with Parkinson's disease?    epda.eu.com

The general ward care (n=20) and the Specialist Parkinson's Unit care (n=24) groups had similar baseline characteristics. On the specialist unit: less Parkinson's medication was omitted (13% v 20%, p[...]

Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series    epda.eu.com

Discussion: Hypersexuality and delusional jealousy may occur independently in PD patients on dopamine agonist therapy, but may develop together probably reflecting a common alteration of sexuality (s[...]

The Cognition & Emotional Well-being indices of the Parkinson's Disease Questionnaire-39: What do they really measure?    epda.eu.com

Conclusions: The PDQ-39 Cognition index may be more related to mood functioning, as opposed to cognitive functioning, and should not be considered a proxy for cognitive functioning. Future studies ar[...]

Success Stories - Reducing the risk of Alzheimer's disease and vascular dementia - World Alzheimer Day 21-09-2014    europa.eu

Dementia is a group of degenerative diseases typically affecting the cognitive abilities of the elderly population. According to the World Health Organization, the estimated proportion of the general[...]

Dementia & severity of parkinsonism determines handicap of patients in late-stage Parkinson's: the BarcelonaLisbon cohort    epda.eu.com

Methods: Handicap, medical conditions, use of healthcare resources and the impact of LS-PD upon caregivers were characterized in a cross-sectional study of LS-PD stages 4 or 5 of Hoehn and Yahr (H&am[...]

Back to the basics: regular exercise matters in Parkinson's: Results from the National Parkinson Foundation registry study    epda.eu.com

Regular exercisers at baseline was associated with better QOL, mobility, and physical function, less progression of disease, less caregiver burden and less cognitive decline one year later, after con[...]

Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis    epda.eu.com

Conclusions ChIs are effective in the treatment of cognitive impairment in patients with PD, but do not affect risk of falls. The choice of treatment has to be balanced considering the increased trem[...]

Dual-task interference and brain structural connectivity in people with Parkinson's disease who freeze    epda.eu.com

These results support the hypothesis that freezing is related to altered attentional control during gait, and suggest that differences in pedunculopontine nucleus connectivity contribute to poorer at[...]

Effects of cognitive training in Parkinson's Disease: a randomized controlled trial    epda.eu.com

Cognitive and affective functions can be improved by cognitive trainings in PD patients. Specific effects (e.g. on memory and working memory versus depression) seem to be dependent on the type of tra[...]

Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease    epda.eu.com

Conclusions: Hippocampal volume is a major factor predicting the development of mild cognitive impairment and dementia in PD. White matter hyperintensity also contributes to the longitudinal cognitiv[...]

Lower plasma Apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype    epda.eu.com

results are compatible with a model whereby circulating ApoA1 levels may be useful in risk-stratifying subjects for the development of PD, with higher ApoA1 levels suggesting relative protection. Fut[...]

Interventions for fatigue in Parkinson's disease: A systematic review and meta-analysis    epda.eu.com

Currently insufficient evidence exists to support the treatment of fatigue in PD with any drug or nondrug treatment. Further study is required.[...]

Midlife migraine and late-life parkinsonism    epda.eu.com

These findings suggest there may be a common vulnerability to, or consequences of, migraine and multiple indicators of parkinsonism. Additional genetic and longitudinal observational studies are need[...]

Puerarin protects dopaminergic neurons in Parkinson's disease models    epda.eu.com

These data indicated that puerarin alleviated the oxidative stress and apoptosis in a PD cellular model, protected the dopaminergic neurons against rotenone toxicity and decreased the abnormal protei[...]

EPDA Move for Change survey shows Parkinson's care standards are lagging just one in 10 patients are diagnosed by a disease ex    epda.eu.com

Care provision in Parkinson's disease is falling dismally short of the standards patients and carers have every right to expect, research across Europe indicates.[...]

The role of iron in brain ageing and neurodegenerative disorders    epda.eu.com

During ageing, different iron complexes accumulate in brain regions associated with motor and cognitive impairment. In various neurodegenerative diseases, such as Alzheimer's disease and Parkinson's [...]

Researchers debunk myth about Parkinson's disease    epda.eu.com

BRAIN RESEARCH - Using advanced computer models, neuroscience researchers at the University of Copenhagen have gained new knowledge about the complex processes that cause Parkinson's disease. The fin[...]

Pooled analysis of phase III with entacapone in Parkinson's disease    epda.eu.com

Conclusions: Entacapone improved daily OFF- and ON-times by a mean of 0.8 h compared with placebo across the four pooled efficacy studies and was generally well tolerated. The results of this pooled [...]

Prevalence of Malnutrition in Patients with Parkinson's: Comparative Study with Healthy Controls using MNA questionnaire    epda.eu.com

Study findings indicate the same nutritional status among mild to moderate PD patients compared with healthy controls. However, more than a quarter of the PD population was found to be at risk of mal[...]

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease    epda.eu.com

This is the first study indicating that the SLC6A3/DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease. This effect is stronger for conditions [...]

Parkinson disease and smoking revisited    epda.eu.com

Authors propose that ease of smoking cessation is an aspect of premanifest PD similar to olfactory dysfunction, REM sleep disorders, or constipation and suggests that the apparent neuroprotective eff[...]

Dance for people with Parkinson's disease: what is the evidence telling us?    epda.eu.com

Conclusions: Dance may be helpful for some people with PD. This paper provides preliminary information to aid clinicians when implementing dance programmes for people with PD. Higher quality multi-ce[...]

Acupuncture on GB34 activates the precentral gyrus and prefrontal cortex in Parkinson's disease    epda.eu.com

Acupuncture stimulation on this acupoint activates the prefrontal cortex, precentral gyrus, and putamen in patients with PD; areas that are known to be impaired in patients with PD. Compared with hea[...]

Survey reveals knowledge gaps among Parkinson's patients and caregivers    epda.eu.com

A recent survey of more than 1,500 Parkinson's disease (PD) patients, caregivers and physicians reveals that information and specialized care can help patients become more engaged in their own treatm[...]

Differentiating drug-induced parkinsonism from Parkinson's disease: An update on non-motor symptoms and investigations    epda.eu.com

Authors performed a review to ascertain whether assessment of non-motor symptoms, or use of ancillary investigations, namely dopamine transporter imaging, transcranial sonography of the substantia ni[...]

Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect    epda.eu.com

Results: Mortality rate was 56.8%. Although higher age (p 0.48).[...]

Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries    epda.eu.com

Objective: To assess QoL and its association with on-off fluctuations, peak-dose dyskinesias, biphasic dyskinesias, and off-dystonias in PD patients from five European countries.[...]

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa    epda.eu.com

Authors conclude that motor fluctuations and dyskinesias are not associated with the duration of levodopa therapy, but rather with longer disease duration and higher levodopa daily dose. Hence, the p[...]

Canadian Study of Neurological Conditions Provides New Vital Information on the Impact of Parkinson's Disease    epda.eu.com

Parkinson Society Canada is excited to share today's release of the report on The National Population Health Study of Neurological Conditions by the Public Health Agency of Canada in partnership with[...]

Short rapid steps to provoke freezing of gait in Parkinson's disease    epda.eu.com

The combination of 'full rapid turns' and 'walking with short steps rapidly' yielded the highest sensitivity of provoking FOG (0.71, CI 0.510.86). The most sensitive way to provoke FOG is by asking p[...]

Dopaminergic agents and nutritional status in Parkinson's disease    epda.eu.com

Results: In linear regression, total levodopa (l-dopa) equivalent daily dose (LEDD) was associated with worse MNA (B = 0.14, 95% CI = 0.26-0.02; P = 0.019). This association remained significant only[...]

Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease    epda.eu.com

Conclusions: STN-DBS decreased pain after surgery, but had different effects in different types of PD-related pain. Motor and nonmotor symptom improvements after STN-DBS did not correlate with pain r[...]

Stimulation of the pedunculopontine nucleus area in Parkinson's disease: effects on speech and intelligibility    epda.eu.com

Although limited in this group of patients, speech impairment following pedunculopontine nucleus area stimulation is a possible outcome that should be considered before undertaking such surgery. Dele[...]

2012 European Year for Active Ageing and Solidarity between generations (EY2012) – Evaluation report    europa.eu

The European Commission has adopted a report today on the implementation, results and overall assessment of the 2012 European Year for Active Ageing and Solidarity between Generations.[...]

Device to help people with Parkinson's disease communicate better now available    epda.eu.com

SpeechVive Inc. announced Wednesday (Sept. 10) the commercial launch of the SpeechVive device intended to help people with a soft voice due to Parkinson's disease speak more loudly and communicate mo[...]

Cortical volume and folding abnormalities in Parkinson's disease patients with pathological gambling    epda.eu.com

This study demonstrates that combined grey matter atrophy and reduced lGI in the OFC differentiates PD patients with PG from those without PG, suggesting that this cortical area may play a critical r[...]

Glucocerebrosidase mutations in primary parkinsonism    epda.eu.com

Conclusion: GBA dysfunction is relevant for synucleinopathies, such as PD and DLB, except for MSA, in which pathology involves oligodendrocytes, and the tauopathies PSP and CBD. The risk of developin[...]

Parkinson's Disease Foundation Announces Newest Series of Community-Driven Online Seminars    epda.eu.com

The Parkinson's Disease Foundation (PDF) is pleased to announce its sixth series of PD ExpertBriefings, free interactive seminars presented by leaders in Parkinson's disease research and care.[...]

'Pocket doctor' phone app could measure Parkinson's progression    epda.eu.com

Parkinson's disease and other degenerative motor system disorders are notoriously difficult to diagnose accurately. But now, new research has resulted in a new application that enables smartphones to[...]

Summary of Optimum Continence Service Specification    epda.eu.com

In this summary document authors have included the results of a model constructed to assess the expected clinical, quality of life and economic impact of this service specification on people with inc[...]

Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic    epda.eu.com

Conclusions: Over the last two decades, age at onset of PD appeared to shift progressively towards more advanced age. However, sequential, high quality population-based incidence studies are required[...]

Stepping out for people with Parkinson's    epda.eu.com

With only a couple of weeks to go until the second European Unity Walk, we are all limbering up for what promises to be a hugely enjoyable and inspirational event.[...]

Active and healthy ageing: the importance of nutrition to add healthy life years    eufic.org

The Joint Research Centre (JRC), the European Commission's in-house science service, has published a science and policy report highlighting the importance of diet and nutrition in increasing healthy [...]

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson's Disease, and Diabetic Neuropathy    epda.eu.com

KineMed, Inc. today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: Compositions and Methods of Treatment Using Mod[...]

Move for Change Part III: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's Disease    epda.eu.com

These results highlight that PD disease-management is driven by the clinician; he/she arranges consultations and makes the majority of management decisions, rather than patients being included in the[...]

Visual short-term memory deficits associated with GBA mutation and Parkinson's disease    epda.eu.com

These findings provide evidence for dissociable signature deficits within the domain of visual short-term memory associated with GBA mutation and with Parkinson's disease. Identification of the speci[...]

Disclaimer

The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.